LIFE aTyr Pharma, Inc.

3.05
+0  (1%)
Previous Close 3.03
Open 3.00
Price To book 1.14
Market Cap 72.43M
Shares 23,748,000
Volume 36,248
Short Ratio 1.93
Av. Daily Volume 146,250

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 1H 2017.
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)

Latest News

  1. aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
  2. aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
  3. aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
  4. Atyr Pharma reports 4Q loss
  5. aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases
  6. aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
  7. aTyr Pharma Rises 16% on Orphan Drug Status
  8. aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference
  9. aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
  10. High court ruling limits international reach of patent laws
  11. Atyr Pharma Stock Spikes 33% on FDA Updates
  12. FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
  13. Roberts recuses from patent case after discovering conflict
  14. Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
  15. Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?
  16. aTyr Pharma Drops on Clinical Update
  17. aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials
  18. aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference
  19. aTyr Pharma Enters into $20 Million Credit Facility